Several brokerages have updated their recommendations and price targets on shares of Bayer AG (OTCMKTS: BAYRY) in the last few weeks:

  • 9/15/2016 – Bayer AG had its “buy” rating reaffirmed by analysts at Sanford C. Bernstein.
  • 9/14/2016 – Bayer AG had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc..
  • 9/13/2016 – Bayer AG was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Bayer’s Life Science businesses continue to perform well, particularly the Pharmaceuticals and Consumer Health businesses. Newly launched products in the Pharmaceuticals segment should continue to perform impressively in the upcoming quarters. Moreover, Bayer has made several acquisitions and entered into a number of deals to boost its portfolio in the past few quarters. In its attempt to create a global leader in agriculture by acquiring Monsanto, Bayer has upped its all-cash offer to Monsanto shareholders from $125 per share to $127.50 per share. We are further pleased with Bayer’s strategy of transforming itself into a pure life science company, which resulted in the sale of its Diabetes Care business and the spin-off of MaterialScience. However, we are concerned about the company’s dependence on the Pharmaceuticals segment for growth. Generic threats/competition remains a concern.”
  • 9/2/2016 – Bayer AG was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $119.00 price target on the stock. According to Zacks, “Bayer’s Life Science businesses continue to perform well, particularly the Pharmaceuticals and Consumer Health businesses. Newly launched products in the Pharmaceuticals segment should continue to perform impressively in the upcoming quarters. Bayer’s raised 2016 core earnings per share outlook is encouraging. Moreover, Bayer has made several acquisitions and entered into a number of deals to boost its portfolio in the past few quarters. We are further pleased with Bayer’s strategy of transforming itself into a pure life science company, which resulted in the sale of its Diabetes Care business and the spin-off of MaterialScience. However, we are concerned about the company’s dependence on the Pharmaceuticals segment for growth. Below-par sales at this segment may weigh heavily on the stock. Generic threats/competition remain a concern. Continued weak performance of key drugs could impact the company’s top line.”
  • 8/25/2016 – Bayer AG was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating.
  • 8/22/2016 – Bayer AG was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Bayer anticipates somewhat sluggish growth in the global economy in 2016. Considering the challenging market environment, the company lowered its expectations for the performance of the Crop Science and Consumer Health segments. Meanhwile, Bayer is facing generic threats/competition for many of its product. Continued weak performance of key drugs could impact the company’s top line. Moreover, we are concerned about the company’s dependence on the Pharmaceuticals segment for growth. Below-par sales at this segment may weigh heavily on the stock. Nevertheless, newly launched products at Pharmaceuticals segment should continue perform well. Bayer’s raised 2016 core earnings per share outlook is encouraging. We are further pleased with Bayer’s strategy of transforming itself into a pure life science company, which resulted in the sale of its Diabetes Care business and the spin-off of MaterialScience.”
  • 8/16/2016 – Bayer AG was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Although Bayer’s second-quarter earnings topped estimates, the company missed expectations marginally on revenues. We are concerned about the company’s dependence on the pharmaceutical segment for growth. Below-par sales at this segment may weigh heavily on the stock. A history of pipeline setbacks, weak global economy outlook and generic competition remain headwinds. Nevertheless, the company’s Life Science businesses recorded sales growth, particularly the Pharmaceuticals and Consumer Health categories. Newly launched products at Pharmaceutical segment performed impressively and should continue to do so in the upcoming quarters. Bayer also raised its core earnings per share outlook for the year, which is encouraging. We are further pleased with Bayer’s strategy of transforming itself into a pure life science company, which resulted in the sale of its diabetes care business and the spin-off of MaterialScience.”

Bayer AG (OTCMKTS:BAYRY) traded up 0.89% during mid-day trading on Tuesday, hitting $102.90. The stock had a trading volume of 51,412 shares. The firm’s 50-day moving average price is $107.18 and its 200-day moving average price is $107.75. The stock has a market cap of $85.09 billion, a PE ratio of 16.84 and a beta of 1.40. Bayer AG has a 1-year low of $94.36 and a 1-year high of $135.71.

Bayer AG is a Germany-based chemical and pharmaceutical company. The Company’s business operations are organized into three segments: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare researches, develops, manufactures and markets products to improve the health of people and animals.

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.